FibroBiologics, Inc.
NCM: FBLGLive Quote
About FibroBiologics, Inc.
Healthcare
Biotechnology
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
📊 Fundamental Analysis
FibroBiologics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -419.4%, which indicates that capital utilization is currently under pressure.
At a current price of $1.35, FBLG currently trades near the bottom of its 52-week range (1%), indicating potential value or weakness (Range: $1.03 - $30.60).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$4.84M
Trailing P/E
--
Forward P/E
-0.25
Beta (5Y)
1.10
52W High
$30.60
52W Low
$1.03
Avg Volume
319K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App